Growth HormoneResearch
Tabimorelin
Also known as: NN703
A potent oral GH secretagogue that reached Phase II clinical trials. Though shelved commercially, it remains a testament to oral secretagogue engineering.
Reviewed by Dr. Sarah Mitchell, PharmD, BCPS
Lead Researcher · 12+ years in peptide therapeutics
Half-Life
~2 hours
Typical Dose
Research dosing
Administration
Oral
Mechanism of Action
Peptide-mimetic that breaches the gastric barrier to activate GHS-R1a receptors and stimulate natural pulsatile GH release from the pituitary.
Key Research Areas
growth hormoneoralsecretagogue
Frequently Asked Questions
What is Tabimorelin?▾
A potent oral GH secretagogue that reached Phase II clinical trials. Though shelved commercially, it remains a testament to oral secretagogue engineering.
How does Tabimorelin work?▾
Peptide-mimetic that breaches the gastric barrier to activate GHS-R1a receptors and stimulate natural pulsatile GH release from the pituitary.
What is the recommended dosage for Tabimorelin?▾
The typical research dosage is Research dosing, administered via Oral. Dosage protocols vary by study and should be determined by a qualified healthcare professional.
What is the half-life of Tabimorelin?▾
The half-life of Tabimorelin is approximately ~2 hours. This affects dosing frequency and timing in research protocols.
Is Tabimorelin FDA approved?▾
Tabimorelin is currently classified as "Research" and is not FDA approved for general use. It is available for research purposes or through compounding pharmacies depending on your jurisdiction.
Research Disclaimer
The information provided about Tabimorelin is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare professional before starting any peptide protocol. Products discussed have not been evaluated by the FDA unless explicitly noted.